Advances in thoracic consolidation radiotherapy after first-line immunotherapy combined with chemotherapy for extensive stage small cell lung cancer
10.3760/cma.j.cn112152-20230828-00102
- VernacularTitle:广泛期小细胞肺癌一线免疫联合化疗后胸部巩固放疗研究进展
- Author:
Wen ZHAO
1
;
Lu WANG
;
Zhaoliang XIE
;
Yanan SONG
;
Xue MENG
;
Jisheng LI
Author Information
1. 山东大学齐鲁医院肿瘤内科，济南 250012
- Keywords:
Lung neoplasms;
Small cell lung cancer;
Extensive stage;
Immune checkpoint inhibitor;
Thoracic consolidation radiotherapy
- From:
Chinese Journal of Oncology
2024;46(6):526-535
- CountryChina
- Language:Chinese
-
Abstract:
Small cell lung cancer (SCLC) accounts for about 13%~17% of primary bronchial lung cancer. Due to its rapid growth rate, aggressive behavior, early metastasis and poor prognosis, about 70% of patients were diagnosed with extensive-stage (ES) disease. Although most ES-SCLC patients are sensitive to initial chemotherapy, local recurrence and distant metastasis develop in the short term. Immunotherapy has brought the dawn to overcome it. At present, immune checkpoint inhibitor combined with chemotherapy has become an important strategy as first-line therapy for ES-SCLC. Nevertheless, patients are still at a high risk of chest lesion recurrence after initial systemic therapy. Whether the addition of thoracic consolidation radiotherapy (TRT) can reduce chest lesion recurrence rate remains to be determined. In this review, we summarized the latest research progress in the mode of first-line chemotherapy combined with immunotherapy followed by TRT in ES-SCLC, aiming to provide reference for clinical practice.
